Celgene Corp. (CELG) Shares Bought by Whittier Trust Co. of Nevada Inc.
Whittier Trust Co. of Nevada Inc. increased its position in shares of Celgene Corp. (NASDAQ:CELG) by 2.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 46,933 shares of the biopharmaceutical company’s stock after buying an additional 1,055 shares during the period. Whittier Trust Co. of Nevada Inc.’s holdings in Celgene Corp. were worth $4,629,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of CELG. Whittier Trust Co. increased its stake in Celgene Corp. by 0.7% in the second quarter. Whittier Trust Co. now owns 122,167 shares of the biopharmaceutical company’s stock worth $12,049,000 after buying an additional 892 shares during the last quarter. ClariVest Asset Management LLC increased its stake in Celgene Corp. by 0.6% in the second quarter. ClariVest Asset Management LLC now owns 215,420 shares of the biopharmaceutical company’s stock worth $21,246,000 after buying an additional 1,253 shares during the last quarter. LMR Partners LLP bought a new stake in Celgene Corp. during the second quarter worth $1,105,000. Trillium Asset Management LLC bought a new stake in Celgene Corp. during the second quarter worth $3,716,000. Finally, Sonata Capital Group Inc. increased its stake in Celgene Corp. by 10.3% in the second quarter. Sonata Capital Group Inc. now owns 4,033 shares of the biopharmaceutical company’s stock worth $398,000 after buying an additional 375 shares during the last quarter. Institutional investors and hedge funds own 77.75% of the company’s stock.
Celgene Corp. (NASDAQ:CELG) traded up 0.04% on Friday, hitting $104.07. 1,871,956 shares of the stock were exchanged. Celgene Corp. has a 12 month low of $93.05 and a 12 month high of $128.39. The company has a 50-day moving average of $107.29 and a 200 day moving average of $105.50. The firm has a market cap of $80.67 billion, a P/E ratio of 43.99 and a beta of 1.49.
Celgene Corp. (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.44 EPS for the quarter, beating the Zacks’ consensus estimate of $1.39 by $0.05. Celgene Corp. had a net margin of 18.95% and a return on equity of 67.06%. The firm had revenue of $2.74 billion for the quarter, compared to analysts’ expectations of $2.70 billion. During the same quarter in the prior year, the company posted $1.23 earnings per share. The business’s revenue for the quarter was up 20.9% on a year-over-year basis. Equities research analysts expect that Celgene Corp. will post $5.71 earnings per share for the current fiscal year.
A number of research firms recently weighed in on CELG. Zacks Investment Research upgraded Celgene Corp. from a “hold” rating to a “buy” rating and set a $117.00 price objective for the company in a report on Friday. Jefferies Group reiterated a “buy” rating and set a $134.00 price target on shares of Celgene Corp. in a report on Thursday. BMO Capital Markets reiterated an “outperform” rating and set a $141.00 price target on shares of Celgene Corp. in a report on Monday, October 3rd. Piper Jaffray Cos. reiterated an “overweight” rating and set a $145.00 price target on shares of Celgene Corp. in a report on Sunday, October 2nd. Finally, Citigroup Inc. increased their price target on Celgene Corp. from $124.00 to $127.00 and gave the stock a “buy” rating in a report on Thursday, September 29th. Three investment analysts have rated the stock with a hold rating and twenty-five have given a buy rating to the company. Celgene Corp. presently has an average rating of “Buy” and a consensus target price of $137.44.
In other news, insider Robert J. Hugin sold 100,000 shares of the stock in a transaction that occurred on Thursday, July 28th. The shares were sold at an average price of $110.00, for a total transaction of $11,000,000.00. Following the sale, the insider now owns 1,022,201 shares in the company, valued at $112,442,110. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Michael A. Friedman sold 56,116 shares of the stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $103.66, for a total transaction of $5,816,984.56. Following the sale, the director now owns 50,000 shares in the company, valued at approximately $5,183,000. The disclosure for this sale can be found here. Insiders own 0.97% of the company’s stock.
About Celgene Corp.
Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corp. (NASDAQ:CELG).
Receive News & Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related companies with MarketBeat.com's FREE daily email newsletter.